ArticleScientific reports2025
Significant reduction in Hepatitis B virus infections following 32 years of universal Hepatitis B vaccination as part of EPI, Thailand.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- National guideline for hepatitis B elimination in Thailand: a decentralized health system model for expanding diagnosis and treatment.Hepatology international · 2026Article
- A Scoping Review and Risk Assessment of Aflatoxin B1 Contamination in Rice, Maize, and Peanut-Based Products Across Selected ASEAN Countries.Foods (Basel, Switzerland) · 2026Review
- Age associated SARS-CoV-2 immune responses provide insights into population immunity over four years since the COVID-19 pandemic.Scientific reports · 2025Article
- Epstein-Barr Virus Seroprevalence in Thailand: A Temporal and Global Perspective with Health Care and Economic Correlations.The American journal of tropical medicine and hygiene · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the impact of Thailand's hepatitis B virus (HBV) National Program Immunization (NPI), 32 years post-implementation, on infection rates and immunity in various age groups. A cross-sectional study involved 6,068 participants aged 6 months to 80 years from four regions in Thailand. Blood samples were tested for HBsAg, anti-HBs, and anti-HBc using a chemiluminescent immunoassay. Data were compared across age groups and with previous surveys from 2004 to 2014. Individuals born after the implementation of the NPI had significantly lower HBV infection rates (p < 0.0001). No HBsAg was detected in individuals under 20 years old. The prevalence of HBV carriers increased with age, from 0.3% in the 21-30 group to 4.3% in those over 60, with an overall prevalence of 1.7%. Percentages of seroprotected individuals (anti-HBs ≥ 10 mIU/mL) were high in young children but dropped to 19.4% in ages 11-20 and 12.5% in ages 21-30. Anti-HBc was found at very low rates in children but increased significantly after age 30. Thailand's HBV NPI significantly reduced HBV infection rates, especially in younger populations. This study highlighted the program's success and guided future elimination efforts to achieve hepatitis elimination goal by 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.